3-Methoxy-2-phenylimidazo[1,2-b]pyridazines highly active against Mycobacterium tuberculosis and Mycobacterium marinum

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2023-11-05 DOI:10.1016/j.ejmech.2023.115637
Kyle D. Farrell , Yamin Gao , Deborah A. Hughes , Robin Henches , Zhengchao Tu , Michael V. Perkins , Tianyu Zhang , Craig L. Francis
{"title":"3-Methoxy-2-phenylimidazo[1,2-b]pyridazines highly active against Mycobacterium tuberculosis and Mycobacterium marinum","authors":"Kyle D. Farrell ,&nbsp;Yamin Gao ,&nbsp;Deborah A. Hughes ,&nbsp;Robin Henches ,&nbsp;Zhengchao Tu ,&nbsp;Michael V. Perkins ,&nbsp;Tianyu Zhang ,&nbsp;Craig L. Francis","doi":"10.1016/j.ejmech.2023.115637","DOIUrl":null,"url":null,"abstract":"<div><p>A series of 3-methoxy-2-phenylimidazo[1,2-<em>b</em>]pyridazine derivatives which were highly active against autoluminescent <em>Mycobacterium tuberculosis</em> (Mtb) and <em>Mycobacterium marinum</em> (Mm) in an <em>in vitro</em> assay were identified. SAR analysis showed that the most active compounds, which included a phenyl group bearing fluoro substituent(s) at C2, a methoxy function at C3, and a benzyl-heteroatom moiety at C6, exhibited <em>in vitro</em> MIC<sub>90</sub> values generally around 0.63–1.26 μM against Mtb and Mm. However, these compounds were inactive against Mtb <em>in vivo</em> (mice), and investigations revealed very short metabolic half-lives (&lt;10 min) when incubated with mouse liver microsomes. Multiple observations of side products produced from oxidative cleavage of the imidazole moiety during the chemical synthesis work suggested that this is a likely metabolic pathway leading to the lack of observed activity <em>in vivo</em>.</p></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"259 ","pages":"Article 115637"},"PeriodicalIF":6.0000,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0223523423006037/pdfft?md5=2d6df61a1fec7e86f4b11a55e07df197&pid=1-s2.0-S0223523423006037-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523423006037","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

A series of 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivatives which were highly active against autoluminescent Mycobacterium tuberculosis (Mtb) and Mycobacterium marinum (Mm) in an in vitro assay were identified. SAR analysis showed that the most active compounds, which included a phenyl group bearing fluoro substituent(s) at C2, a methoxy function at C3, and a benzyl-heteroatom moiety at C6, exhibited in vitro MIC90 values generally around 0.63–1.26 μM against Mtb and Mm. However, these compounds were inactive against Mtb in vivo (mice), and investigations revealed very short metabolic half-lives (<10 min) when incubated with mouse liver microsomes. Multiple observations of side products produced from oxidative cleavage of the imidazole moiety during the chemical synthesis work suggested that this is a likely metabolic pathway leading to the lack of observed activity in vivo.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
3-甲氧基-2-苯基咪唑并[1,2-b]哒嗪对结核分枝杆菌和海洋分枝杆菌具有高活性。
在体外试验中鉴定了一系列对结核分枝杆菌(Mtb)和海洋分枝杆菌(Mm)具有高活性的3-甲氧基-2-苯基咪唑并[1,2-b]哒嗪衍生物。SAR分析表明,最具活性的化合物,包括C2处带有氟取代基的苯基、C3处的甲氧基官能团和C6处的苄基杂原子部分,在体外对Mtb和Mm的MIC90值通常约为0.63-1.26μM。然而,这些化合物在体内对Mtb(小鼠)无活性,研究显示代谢半衰期非常短(
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
期刊最新文献
Discovery of Potent and Selective Factor XIa Inhibitors Incorporating Triazole-Based Benzoic Acid as Novel P2’ Fragments: Molecular Dynamics Simulations and Anticoagulant Activity Design, synthesis, and biological evaluation of novel highly potent FXR agonists bearing piperidine scaffold Design, synthesis and anti-tumor evaluation of novel pyrimidine and quinazoline analogues Optimization of SHP2 Allosteric Inhibitors with Novel Tail Heterocycles and Their Potential as Antitumor Therapeutics Discovery of a Highly Potent, N-terminal Domain-targeting degrader of AR-FL/AR-V7 for the treatment of Prostate Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1